Log In
Print
BCIQ
Print
Print this Print this
 

FT1050

  Manage Alerts
Collapse Summary General Information
Company Fate Therapeutics Inc.
DescriptionSmall molecule prostaglandin E2 analog
Molecular Target Prostaglandin E2 (PGE2) receptor
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard Indication Hematology (unspecified)
Indication DetailsEx vivo treatment of allogeneic bone marrow stem cells and umbilical cord blood cells to treat acute myelogenous leukemia (AML); Hematopoietic stem cell (HSC) support in patients undergoing non-myeloablative therapy
Regulatory Designation

U.S. - Orphan Drug (Ex vivo treatment of allogeneic bone marrow stem cells and umbilical cord blood cells to treat acute myelogenous leukemia (AML));
EU - Orphan Drug (Ex vivo treatment of allogeneic bone marrow stem cells and umbilical cord blood cells to treat acute myelogenous leukemia (AML))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today